Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Interest & Investment Income: 2019-2024

Historic Interest & Investment Income for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $24.1 million.

  • Lyell Immunopharma's Interest & Investment Income fell 45.25% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year decrease of 41.58%. This contributed to the annual value of $24.1 million for FY2024, which is 2.62% up from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Interest & Investment Income is $24.1 million, which was up 2.62% from $23.5 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Interest & Investment Income peaked at $24.1 million during FY2024, and registered a low of $1.2 million during FY2021.
  • For the 3-year period, Lyell Immunopharma's Interest & Investment Income averaged around $18.2 million, with its median value being $23.5 million (2023).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 80.38% in 2021, then surged by 505.41% in 2022.
  • Yearly analysis of 5 years shows Lyell Immunopharma's Interest & Investment Income stood at $5.9 million in 2020, then tumbled by 80.38% to $1.2 million in 2021, then surged by 505.41% to $7.1 million in 2022, then skyrocketed by 232.53% to $23.5 million in 2023, then grew by 2.62% to $24.1 million in 2024.